Updates in the Management of Newly Diagnosed Acute Myeloid Leukemia

There is a need for improved therapeutic strategies to manage acute myeloid leukemia (AML) disease progression, especially in older patients. Based on the cytogenetic and molecular risk stratification, the use of novel targeted treatment options in the first line setting is associated with improved clinical outcomes and fewer side effects compared to the conventional chemotherapy regimens. Informing clinicians about these therapeutic advances will aid in their incorporation into standard treatment protocols for the appropriate subgroups of patients with AML.

Target Audience

This activity is designed to meet the educational needs of oncologists, hematologists, nurse practitioners, nurses, pharmacists, physician assistants, and other health care professionals who manage patients with hematologic malignancies.

Learning Objectives

Following this program, participants should be able to:

  • Review the current treatment strategies for acute myeloid leukemia (AML).
  • Identify the cytogenetic and/or molecular markers with prognostic significance in AML.
  • Discuss the emerging therapeutic strategies with targeted agents for the management of patients with untreated AML.
Additional information
Supporters: 

This activity is supported by educational grants from: 

  • AstraZeneca
  • Daiichi Sankyo 
  • Gilead Sciences, Inc. and Kite, A Gilead Company
  • GlaxoSmithKline
  • Novartis
  • Pfizer Inc.
  • Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
  • Seagen Inc. (formerly Seattle Genetics, Inc.)
  • Takeda

This activity is supported by independent medical education grants from:

  • ADC Therapeutics
  • Bristol Myers Squibb
  • MorphoSys
  • Pharmacyclics LLC and Janssen and Jazz Pharmaceuticals

This educational activity is supported by a medical education grant from Karyopharm® Therapeutics.

This activity is supported by an independent educational grant from Merck & Co., Inc.

Course summary
Available credit: 
  • 0.75 AAPA Category 1 CME credit
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC contact hours
  • 0.75 Participation
Course opens: 
12/15/2021
Course expires: 
12/15/2022
Cost:
$0.00

Alice S. Mims, MD, MS
The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute

 

NCCN Medical Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.

In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing. 

Definitions  

Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. 

Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.

Faculty Disclaimers  

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.

Faculty Disclosures

Presenting Faculty

The faculty listed below has the following relevant financial relationships with ineligible companies to disclose.  All of the relevant financial relationships listed for these individuals have been mitigated.

Alice S. Mims, MD, MS
AbbVie, Inc.: Consulting Fee
Astellas Pharma US, Inc.: Consulting Fee
Bristol-Myers Squibb Company: Consulting Fee
Daiichi-Sankyo Co.: Consulting Fee
Genentech, Inc.: Consulting Fee
Jazz Pharmaceuticals Inc.: Consulting Fee
Kura Oncology, Inc.: Consulting Fee
Syndax Pharmaceuticals Inc.: Consulting Fee

Moderator

The faculty listed below has the following relevant financial relationships with ineligible companies to disclose.  All of the relevant financial relationships listed for these individuals have been mitigated.

Gabriel Mannis, MD
AbbVie, Inc.: Consulting Fee; Scientific Advisor
Agios, Inc.: Consulting Fee; Scientific Advisor
Astellas Pharma US, Inc.: Scientific Advisor
Astex Pharmaceuticals: Grant/Research Support
Bristol-Myers Squibb Company: Scientific Advisor
Forty Seven, Inc.: Scientific Advisor
Genentech, Inc.: Consulting Fee; Scientific Advisor
Gilead Sciences, Inc.: Grant/Research Support
GlycoMimetics, Inc.: Grant/Research Support
Jazz Pharmaceuticals Inc.: Grant/Research Support
MacroGenics: Consulting Fee
Pfizer Inc.: Scientific Advisor
Stemline Therapeutics, Inc.: Scientific Advisor

NCCN Staff Disclosures

None of the planners for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

image

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians
NCCN designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
NCCN designates this educational activity for a maximum of 0.75 contact hour.

Pharmacists
NCCN designates this knowledge-based continuing education activity for 0.75 contact hour (0.075 CEUs) of continuing education credit. UAN: JA4008196-0000-21-114-H01-P

Physician Assistants 
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.75 AAPA Category 1 CME credit. Approval is valid until December 15, 2022. PAs should only claim credit commensurate with the extent of their participation.

Available Credit

  • 0.75 AAPA Category 1 CME credit
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC contact hours
  • 0.75 Participation

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
    • One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
    • Internet Explorer is no longer supported
  • Adobe Reader or other PDF reader software for certificate viewing/printing